1. Home
  2. KINS vs VNDA Comparison

KINS vs VNDA Comparison

Compare KINS & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KINS

Kingstone Companies Inc.

N/A

Current Price

$18.13

Market Cap

284.5M

Sector

Finance

ML Signal

N/A

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

N/A

Current Price

$4.86

Market Cap

301.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KINS
VNDA
Founded
1886
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
284.5M
301.1M
IPO Year
2013
2005

Fundamental Metrics

Financial Performance
Metric
KINS
VNDA
Price
$18.13
$4.86
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $11.75
AVG Volume (30 Days)
70.8K
★ 598.5K
Earning Date
11-05-2026
10-28-2026
Dividend Yield
★ 1.30%
N/A
EPS Growth
★ 94.59
N/A
EPS
★ 0.66
N/A
Revenue
$214,867,301.00
★ $216,105,000.00
Revenue This Year
$18.83
$15.16
Revenue Next Year
$15.85
$35.50
P/E Ratio
$27.24
★ N/A
Revenue Growth
★ 38.50
8.72
52 Week Low
$13.83
$4.27
52 Week High
$20.90
$9.91

Technical Indicators

Market Signals
Indicator
KINS
VNDA
Relative Strength Index (RSI) 28.88 39.46
Support Level $14.19 $4.45
Resistance Level $17.61 $5.37
Average True Range (ATR) 0.50 0.16
MACD -0.18 -0.01
Stochastic Oscillator 7.06 8.16

Price Performance

Historical Comparison
KINS
VNDA

About KINS Kingstone Companies Inc.

Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: